Free Trial

Nanobiotix (NBTX) Competitors

Nanobiotix logo
$5.01 +0.28 (+5.92%)
Closing price 07/3/2025 03:29 PM Eastern
Extended Trading
$5.08 +0.08 (+1.50%)
As of 07/3/2025 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NBTX vs. LENZ, CRMD, OCS, RCUS, AVXL, COGT, CMRX, CDMO, AVBP, and SNDX

Should you be buying Nanobiotix stock or one of its competitors? The main competitors of Nanobiotix include LENZ Therapeutics (LENZ), CorMedix (CRMD), Oculis (OCS), Arcus Biosciences (RCUS), Anavex Life Sciences (AVXL), Cogent Biosciences (COGT), Chimerix (CMRX), Avid Bioservices (CDMO), ArriVent BioPharma (AVBP), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical products" industry.

Nanobiotix vs. Its Competitors

Nanobiotix (NASDAQ:NBTX) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Nanobiotix has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.

LENZ Therapeutics has lower revenue, but higher earnings than Nanobiotix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nanobiotix$39.18M6.03-$73.73MN/AN/A
LENZ TherapeuticsN/AN/A-$49.77M-$1.77-18.38

In the previous week, LENZ Therapeutics had 3 more articles in the media than Nanobiotix. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Nanobiotix. LENZ Therapeutics' average media sentiment score of 0.93 beat Nanobiotix's score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Nanobiotix Neutral
LENZ Therapeutics Positive

Nanobiotix currently has a consensus price target of $8.00, indicating a potential upside of 59.68%. LENZ Therapeutics has a consensus price target of $46.60, indicating a potential upside of 43.23%. Given Nanobiotix's higher probable upside, equities analysts plainly believe Nanobiotix is more favorable than LENZ Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nanobiotix
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
LENZ Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17

38.8% of Nanobiotix shares are held by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are held by institutional investors. 3.5% of Nanobiotix shares are held by insiders. Comparatively, 6.9% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nanobiotix's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NanobiotixN/A N/A N/A
LENZ Therapeutics N/A -23.74%-22.65%

Summary

LENZ Therapeutics beats Nanobiotix on 9 of the 13 factors compared between the two stocks.

Get Nanobiotix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NBTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NBTX vs. The Competition

MetricNanobiotixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$229.54M$2.43B$5.56B$9.05B
Dividend YieldN/A1.78%5.24%3.99%
P/E RatioN/A9.0227.6520.23
Price / Sales6.03680.43419.56119.26
Price / CashN/A21.7726.2128.59
Price / Book-3.324.558.035.65
Net Income-$73.73M$31.26M$3.18B$249.15M
7 Day Performance8.68%3.25%2.93%3.28%
1 Month Performance6.37%3.46%1.72%3.95%
1 Year Performance-8.24%0.77%34.39%20.98%

Nanobiotix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBTX
Nanobiotix
1.6861 of 5 stars
$5.01
+5.9%
$8.00
+59.7%
-8.2%$229.54M$39.18M0.00100Positive News
Gap Up
LENZ
LENZ Therapeutics
1.3424 of 5 stars
$29.31
-2.9%
$46.60
+59.0%
+80.2%$849.45MN/A-16.56110
CRMD
CorMedix
2.5782 of 5 stars
$12.32
-1.4%
$17.14
+39.1%
+182.5%$847.81M$43.47M56.0030Analyst Revision
High Trading Volume
OCS
Oculis
1.7287 of 5 stars
$19.41
+0.3%
$35.33
+82.0%
+62.6%$844.87M$780K-7.352News Coverage
RCUS
Arcus Biosciences
2.774 of 5 stars
$8.17
+2.8%
$21.29
+160.5%
-40.0%$841.79M$258M-1.95500
AVXL
Anavex Life Sciences
3.6022 of 5 stars
$9.22
-2.7%
$44.00
+377.2%
+155.8%$809.33MN/A-16.7640Positive News
COGT
Cogent Biosciences
2.5922 of 5 stars
$7.18
+1.1%
$14.43
+101.0%
-9.8%$808.38MN/A-3.9080News Coverage
Analyst Revision
CMRX
Chimerix
0.6197 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212K-9.0990
CDMO
Avid Bioservices
0.6863 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+68.4%$799.18M$139.91M-5.23320High Trading Volume
AVBP
ArriVent BioPharma
1.7389 of 5 stars
$21.77
-5.0%
$40.00
+83.7%
+11.6%$783.81MN/A-5.7740
SNDX
Syndax Pharmaceuticals
3.1224 of 5 stars
$9.36
+3.5%
$35.80
+282.5%
-55.7%$777.87M$23.68M-2.42110

Related Companies and Tools


This page (NASDAQ:NBTX) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners